Molecular Specialties, Inc.
   Home  |  Sectors  |  About Us   |  News / Notes  |  Contact Us  |  Links

History & Facts

BUSINESS OVERVIEW:
On June 2002 an agreement was finalized between Molecular Specialties, Inc. and Intermagnetics General Corporation (IGC) to transfer the Electron Paramagnetic Resonance (EPR) assets of IGC-Medical Advances to Molecular Specialties. The EPR assets were originally acquired by IGC in March 1997 as part of the purchase off all of the business assets of Medical Advances, Inc. (MAI). This Milwaukee based company was founded in 1985 as a technology transfer from the Medical College of Wisconsin to develop, manufacture and market RF coils for the MRI industry. The EPR products were included in the original technology transfer, but were never central to the MRI market. These products fulfill a niche market among members of the EPR research community. The role of Molecular Specialties is to continue to serve this community.

As the result of discussions on collaboration in September 2002, Stelar, s.r.l. and Molecular Specialties, Inc. entered into an agreement in which Molecular Specialties servers as the North American marketing entity for Stelar's Spinmaster FFC 2000 1T fast field cycling NMR relaxometer and companion instrument SMARtracer Bench-Top FFC NMR Relaxometer. Stelar has taken orders and installed 25 FFC NMR instruments in Europe and one each in India, Saudi Arabia and Japan. There are five instruments installed in North America. The principals of Stelar and Molecular Specialties have known each other and worked together in other areas of NMR for the past 19 years.

In July 2008 Molecular Specialties was issued a patent titled "System for Concurrent MRI Imaging and Magnetic Field Homogeneity Measurement". This element of intellectual property will give Molecular Specialties a potential position to licence the technology to medical device companies serving the MRI and fMRI markets.

Business Plan/Strategy
There is a proposed concept in university-based technology transfer to create companies that can commercialize "orphan" or narrow market products. A company of this nature in its initial strategy will create a commercial platform for products and technologies that because of limited market size would not be attractive to larger enterprises, but will fill a void in market demand. Furthermore, the concept of this sort of company is not driven by investors demanding a "cash out" plan. A very successful business can be formed around an annual revenue stream of $2 million to $5 million. The concept is to create a business model that generates jobs in the high technology sector and products that can support the mission of scientific and medical researchers worldwide. For the universities that are the origin of the technology, royalties based on licensing the technology could be expected. Without the "small company model", esoteric and narrow market technologies may languish in the files of university technology transfer offices.

Molecular Specialties is a model of a company that can transfer university-based technology into "orphan" or narrow scientific and clinical markets. The foundation market to be addressed by Molecular Specialties will be electron paramagnetic resonance (EPR) scientific community. This area of science explores molecular structures using principles of biophysics and microwaves as the measurement tool. At the Medical College of Wisconsin located in the Department of Biophysics (formerly Biophysics Research Institute) is the National Biomedical ESR Center. This Federal Government funded laboratory has an international reputation, and is one of the largest ESR/EPR research centers in the world. The principal of Molecular Specialties has had a 25-year working relationship with the forerunner Biophysics Research Institute. The licensing of intellectual property has been pursued by the Company from the Medical College of Wisconsin to market microwave probes and accessories developed in the Department of Biophysics. These products have been put into practice in EPR research laboratories. Additional EPR products are being developed and patented by the Medical College of Wisconsin in collaboration with the Jagiellonian University, Krakow, Poland. Molecular Specialties may be used as a conduit to take these new products to market.

Besides the EPR product offering, Molecular Specialties is interested in working with the technology transfer offices of universities to identify additional possible business opportunities synergistic with the Company's marketing strengths and business strategy.

All production of Molecular Specialties products is being out sourced from suppliers who have expertise in engineering, fabrication and the manufacture of products to be offered.

Molecular Specialties, Inc.
10437 Innovation Drive   Suite #301   Milwaukee, WI 53226  -  Call: 414-258-6724

^^ top of page ^^

© 2003-09 Molecular Specialties, Inc. All rights reserved.